Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting
Rhea-AI Summary
Catheter Precision (NYSE:VTAK) will attend the 47th Heart Rhythm Society meeting in Chicago, April 24–27, 2026, featuring the VIVO system in a poster (April 24) and a core-session presentation (April 25). Two new peer‑reviewed papers for LockeT (139 patients) and VIVO (31 patients, 48 VTs) are published online.
The announcements emphasize feasibility data for intracardiac VT localization, workflow benefits for VT ablation, and LockeT venous‑closure outcomes including high procedural success and low complication rates.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – VTAK
On the day this news was published, VTAK declined 1.94%, reflecting a mild negative market reaction. Argus tracked a trough of -23.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $51K from the company's valuation, bringing the market cap to $2.58M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VTAK was up about 1.05% with mixed peer moves: NUWE down 3.77%, NAOV down 1.95%, while BBLG and VERO were modestly positive. This pattern points to stock-specific rather than broad sector momentum.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 01 | VIVO clinical data | Positive | -3.9% | New Heart Rhythm conference data showed >95% mapping accuracy and shorter procedures. |
| Nov 04 | VIVO EU registry data | Positive | +0.4% | SCRN meeting data from 27-subject VIVO EU registry with high ablation success and freedom from VT. |
| Oct 02 | VIVO study update | Positive | -5.8% | ESC data on 20-patient VIVO study with 90% success and expanding commercial interest. |
Clinical data updates on VIVO often read positively but have historically produced modest or negative next-day moves, with 2 of 3 prior same-tag events selling off despite favorable data.
Over the past two years, VTAK has repeatedly highlighted new clinical data for its VIVO mapping system at major cardiology forums. At Heart Rhythm 2025 and SCRN, VIVO data showed high mapping accuracy and strong ablation outcomes across studies involving 20–27 patients. Despite these encouraging results, the stock’s 24-hour reactions were often negative, including a -5.77% move after an October 2024 update. Today’s Heart Rhythm Society announcement continues this pattern of expanding evidence and conference visibility for VIVO.
Historical Comparison
In the past 18 months, VTAK released 3 clinical-data updates on VIVO around major conferences, averaging a -3.09% next-day move, so reactions to new HRS data have often been muted or negative.
Clinical evidence for VIVO has progressed from single-center and registry results with high accuracy and success rates toward broader conference exposure and journal publications, reinforcing adoption signals over time.
Market Pulse Summary
This announcement highlights expanding clinical validation and conference visibility for VIVO and LockeT, including studies of 139 and 31 patients and publication in leading EP journals. Historically, similar clinical-data releases averaged a -3.09% next-day move, suggesting that favorable science has not always translated into stock strength. Investors may focus on how these data support adoption, revenue growth, and the company’s ability to address disclosed liquidity and going-concern risks in recent SEC filings.
Key Terms
cardiac electrophysiology medical
electrophysiology (EP) medical
ventricular tachycardia (VT) medical
intracardiac electrogram medical
12-lead ECG medical
3D mapping medical
electroanatomical mapping medical
venous closure medical
AI-generated analysis. Not financial advice.
VIVO System to be featured in educational sessions at HRS
Accepted manuscripts for LockeT and VIVO are now published and available online
FORT MILL, S.C., April 23, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 47th annual Heart Rhythm Society (HRS) meeting. The HRS meeting will take place from April 24th to the 27th in Chicago, Illinois.
HRS announced that the 47th conference will bring together more than 10,000 professionals worldwide for a global exchange of science and innovation advancing electrophysiology (EP). Designed by and for heart rhythm professionals, the meeting features almost 2,000 sessions, posters, roundtables, and hands-on experiences highlighting the latest breakthroughs in arrhythmia care.
Heart Rhythm 2026 received the highest number of abstract submissions in its history, including a fourfold increase in late-breaking science over the past decade, a testament to the rapid growth in the EP field. The meeting continues to serve as a premier forum where practice-changing research is unveiled, sparking the most important conversations and fueling unprecedented scientific advancement across the field.
New Data Presented at the Heart Rhythm Society Meeting
One abstract on Catheter Precision’s VIVO system was accepted and the data will be presented in a poster format on Friday, April 24. In addition, Professor Tarvinder Dhanjal was invited to speak during a core session on the VIVO system on Saturday, April 25.
- Friday April 24, 2026 – Ventricular arrythmia localization using implanted cardioverter defibrillator intracardiac electrogram recordings
- This study is novel and the first to demonstrate feasibility of using intra-cardiac electrodes rather than a surface 12-lead ECG to accurately identify ventricular tachycardia (VT)
- While more research is being conducted, this feasibility indicated VIVO may provide patients with safer VT diagnosis and allow treatment for a currently difficult to treat patient population
- Saturday, April 25, 2026 – Leveraging recorded CIED and EKG data in creating integrated models for accurate localization of arrythmias with real time 3D mapping
- This session will highlight VIVO’s benefits for improved workflow and accurate localization to improve the identification of areas of interest for ventricular ablation procedures
New Publications for Both LockeT and VIVO are Available Online
Recently, Catheter Precision announced the acceptance of two publications, one for LockeT and one for VIVO, in leading electrophysiology journals.
New data demonstrating the benefits of LockeT in large-bore electrophysiology procedures was accepted by the Journal of Cardiovascular Electrophysiology. This study, found here, included 139 patients and concluded that LockeT demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates for venous closure following EP procedures requiring large-bore venous access (LBVA). These findings support LockeT as a feasible and effective venous closure strategy in contemporary EP practice.
A new VIVO study was accepted by leading European journal, EP Europace. This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. The study concluded that VIVO can accurately predict the arrhythmogenic substrate for scar-dependent VT and incorporation of VIVO mapping to conventional VT ablation workflows improves procedural efficiency.
David Jenkins, CEO of Catheter Precision, said, “Having an abstract accepted at any conference is an accomplishment. Somewhere around
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding our anticipation HRS 2026 will be a symposium where we not only demonstrate our products to new and existing customers, but where we can share new and exciting research, like the new peer-reviewed publications, that validate our products to the EP community. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
IR@catheterprecision.com
# # #
